Cargando…

Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)

Duchenne muscular dystrophy (DMD) is the most common degenerative neuromuscular disease. The incidence of DMD in live births is 1/3,600-1/6,000. Although glucocorticoid-dependent medication is the mainstay treatment option for DMD, a standard treatment regimen has yet to be determined. The present r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tianyuan, Kong, Xiangdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967797/
https://www.ncbi.nlm.nih.gov/pubmed/33777191
http://dx.doi.org/10.3892/etm.2021.9875
_version_ 1783665956794400768
author Zhang, Tianyuan
Kong, Xiangdong
author_facet Zhang, Tianyuan
Kong, Xiangdong
author_sort Zhang, Tianyuan
collection PubMed
description Duchenne muscular dystrophy (DMD) is the most common degenerative neuromuscular disease. The incidence of DMD in live births is 1/3,600-1/6,000. Although glucocorticoid-dependent medication is the mainstay treatment option for DMD, a standard treatment regimen has yet to be determined. The present review discusses the literature on the timing, methods and courses of glucocorticoid treatment for DMD. The review highlights the importance of the immediate commencement of glucocorticoid treatment following the diagnosis of DMD, with weekend-only administration being advantageous. Adherence to long-term single-glucocorticoid therapy can delay the loss of ambulation ability, and the side effects of the treatment are controllable. However, the standard medication for patients of different ages and stages of disease development, and the use of combination therapy require further investigation.
format Online
Article
Text
id pubmed-7967797
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-79677972021-03-25 Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review) Zhang, Tianyuan Kong, Xiangdong Exp Ther Med Review Duchenne muscular dystrophy (DMD) is the most common degenerative neuromuscular disease. The incidence of DMD in live births is 1/3,600-1/6,000. Although glucocorticoid-dependent medication is the mainstay treatment option for DMD, a standard treatment regimen has yet to be determined. The present review discusses the literature on the timing, methods and courses of glucocorticoid treatment for DMD. The review highlights the importance of the immediate commencement of glucocorticoid treatment following the diagnosis of DMD, with weekend-only administration being advantageous. Adherence to long-term single-glucocorticoid therapy can delay the loss of ambulation ability, and the side effects of the treatment are controllable. However, the standard medication for patients of different ages and stages of disease development, and the use of combination therapy require further investigation. D.A. Spandidos 2021-05 2021-03-01 /pmc/articles/PMC7967797/ /pubmed/33777191 http://dx.doi.org/10.3892/etm.2021.9875 Text en Copyright: © Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Zhang, Tianyuan
Kong, Xiangdong
Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)
title Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)
title_full Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)
title_fullStr Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)
title_full_unstemmed Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)
title_short Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)
title_sort recent advances of glucocorticoids in the treatment of duchenne muscular dystrophy (review)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967797/
https://www.ncbi.nlm.nih.gov/pubmed/33777191
http://dx.doi.org/10.3892/etm.2021.9875
work_keys_str_mv AT zhangtianyuan recentadvancesofglucocorticoidsinthetreatmentofduchennemusculardystrophyreview
AT kongxiangdong recentadvancesofglucocorticoidsinthetreatmentofduchennemusculardystrophyreview